BRC Therapeutics Celebrates Landmark Executive Order on Cannabis Reclassification

BRC Therapeutics Applauds Executive Order for Cannabis Reclassification

Monterey, California, December 19, 2025 - BRC Therapeutics (BRC), a leading pharmaceutical company dedicated to creating innovative therapeutics for neurological and inflammatory diseases, is rejoicing after the recent executive order that reclassifies cannabis, moving it from the restrictive Schedule I category to Schedule III under the Controlled Substances Act. This pivotal decision aligns federal policy with practices already in place in 40 states and highlights the significant medicinal potential of cannabis-derived compounds, commonly known as cannabinoids.

The shift in classification is expected to streamline and expedite the development and commercialization of cannabinoid medicines, a move BRC has been preparing for while operating under the strict regulations set by the Drug Enforcement Agency (DEA). With all necessary licenses for research activities and production under current Good Manufacturing Practices (cGMP), BRC is well-positioned to leverage this regulatory transformation.

George Hodgin, CEO and Founder of BRC Therapeutics, stated, "This reclassification marks a revolutionary moment for the realm of science and healthcare, particularly for the millions of patients who are in search of effective new treatment options. The previous Schedule I status significantly hindered research and development; however, yesterday's executive order signals that we are on the cusp of removing a significant barrier."

BRC's portfolio includes two investigational products currently undergoing clinical trials. These are aimed at treating Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA). The anticipated regulatory changes due to this order could accelerate progress, enabling quicker advancements in the development of these promising cannabinoid-based therapies.

"We are optimistic that adjusting cannabis' status will foster rigorous scientific exploration and pave the way for a new era of non-addictive and evidence-based treatments for pain relief and other conditions where cannabinoids show a marked therapeutic advantage, " added Hodgin.

About BRC Therapeutics
BRC Therapeutics focuses on developing groundbreaking therapeutic solutions intended to alleviate pain and alleviate symptoms in both acute and chronic illnesses. The company's product line comprises multi-modal medications that utilize cannabinoids in defined ratios to achieve their effects. With ongoing research in neurological and inflammatory disorders, BRC remains dedicated to advancing medicine. The firm operates out of Monterey, California, and is fully compliant with all DEA regulations.

For more information about BRC, visit brctherapeutics.com.

Forward-Looking Statements
The statements within this news release might be forward-looking as per Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. They involve inherent risks, uncertainties, and assumptions regarding the development, uses, and benefits of BRC's therapeutic products and technology. Statements may include words such as "may," "will," "should," "expect," "anticipate," and similar expressions. Actual outcomes may vary significantly from anticipated results due to various risk factors. Consequently, BRC undertakes no obligation to update these forward-looking statements unless necessary by law.